← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	4,391	-60	-1%	$713B
2	2 Amgen AMGN $234B	3,153	+54	+2%	$155B
3	3 Pfizer PFE $168B	2,965	+41	+1%	$106B
4	4 McKesson MCK $117B	2,050	+43	+2%	$92.4B
5	5 Becton Dickinson BDX $51.9B	1,476	-79	-5%	$42.1B
6	6 Regeneron Pharmaceuticals REGN $81.3B	1,401	+10	+0.7%	$69.8B
7	7 AstraZeneca AZN $256B	1,386	-24	-2%	$152B
8	8 Novo Nordisk NVO $171B	1,281	-142	-10%	$12B
9	9 ResMed RMD $33.6B	946	-3	-0.3%	$21.8B
10	10 Conagra Brands CAG $6.87B	793	-5	-0.6%	$6.41B
11	11 West Pharmaceutical WST $26.8B	756	-49	-6%	$17.8B
12	12 Teva Pharmaceutical Industries Limited TEVA $48.2B	654	+20	+3%	$20.1B
13	13 DaVita DVA $11.9B	584	+49	+9%	$9.54B
14	14 Lamb Weston LW $7.34B	567	-60	-10%	$5.44B
15	15 The Magnum Ice Cream Company N.V. MICC $11.3B	499	-67	-12%	$3.66B
16	16 Hims & Hers Health HIMS $6.48B	436	-50	-10%	$3.1B
17	17 Viking Therapeutics VKTX $3.2B	414	-13	-3%	$2.43B
18	18 Madrigal Pharmaceuticals MDGL $10.5B	380	-7	-2%	$12.4B
19	19 BellRing Brands BRBR $1.07B	378	-45	-11%	$2B
20	20 Embecta EMBC $359M	340	-23	-6%	$536M
21	21 Inspire Medical Systems INSP $2.01B	301	-42	-12%	$1.8B
22	22 Rhythm Pharmaceuticals RYTM $5.96B	285	+5	+2%	$6.42B
23	23 Biohaven BHVN $1.64B	278	+5	+2%	$1.2B
24	24 Scholar Rock SRRK $4.84B	274	0	0%	$6.53B
25	25 Herbalife HLF $1.52B	253	+22	+10%	$1.54B